MAPT and Alzheimer disease: Elevated plasma levels of tau are associated with cognitive impairment and brain atrophy and are predictive of future rates of cognitive decline in AD patients (Gómez-Ramos et al., 2006; Zetterberg et al., 2013; Blennow, 2017; Deters et al., 2017).